際際滷

際際滷Share a Scribd company logo

2018 jp morgan final 01.07.18

P
pfizer_ir

This document summarizes Dr. Mikael Dolsten's presentation at the JP Morgan Healthcare Conference on Pfizer's R&D productivity. Some of the key points include: - Pfizer expects up to 15 potential blockbuster drug approvals between 2017-2022 across areas like oncology, inflammation/immunology, vaccines, and rare diseases. - Between 2005-2010 Pfizer had 2 potential blockbuster approvals, between 2011-2016 there were 5, and between 2017-2022 they expect up to 15. - Some of the potential blockbuster drugs highlighted include talazoparib, lorlatinib, tanezumab, rivipansel, tafamidis,

1 of 5
Download to read offline
JP Morgan Healthcare Conference A New Era of Pfizer R&D Productivity Mikael Dolsten, M.D., Ph.D. President, Worldwide R&D January 8, 2018
Forward-Looking Statements This presentation includes forward-looking statements about, among other things, our in-line products and product candidates, including anticipated regulatory submissions, data read-outs, approvals, performance, timing of exclusivity, potential benefits of Pfizer's products and product candidates, and anticipated future operating and financial performance that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.
12. domagrozumab Duchenne 13. rivipansel Sickle Cell 14. tafamidis Cardiomyopathy 15. tanezumab Pain Step Change in Pfizer R&D Productivity Actual and potential blockbuster approvals (as of January 2018) Up to 15 in 5 Years* Note: Examples reflect when cumulative Peak Year Sales are anticipated to exceed $1B. 1. IO-IO: Mono/Combo 2. IO-Targeted / IO-Chemo 3. Targeted Cancer Agents (Collective) (talazoparib, lorlatinib, dacomitinib, glasdegib) 4. Ibrance速 Intermediate/High Risk eBC 5. Xtandi速 non meta. PROSPER/EMBARK 6. JAK1 Atopic Dermatitis 7. JAK X Alopecia/Vitiligo 8. Xeljanz LCM 9. Clostridium Difficile 10. Staphylococcus Aureus 11. Pneumococcal Nextgen 2005-2010 2011-2016 2017-2022 Inflammation & immunology Oncology Vaccines Rare Disease & Internal Med Pre/Early Wyeth R&D Transformation Return to Growth (Infant ) (Adult) 2 5 *Subject to attrition
Potential 2018 Milestones 4 talazoparib EMBRACA Submission (US/EU) Bavencio速 NSCLC 2L Phase 3 Data TFPI mAb Hemophilia Phase 1b/2 Data JAK3 Rheumatoid Arthritis Phase 1 Data Anti IL-33 Atopic Derm Phase 1 Data 1H 2018 2H 2018 LATE STAGE EARLY STAGE Ibrance速 Combo PDAC Phase 1 Data lorlatinib NSCLC 2L Action Date (US) rivipansel Sickle Cell Phase 3 Data tanezumab OA/CLBP Pain Phase 3 Data Xeljanz速 Ulcerative Colitis Action Date (US/EU) Selective JAKs Alopecia, Psoriasis Phase 2 Data PNG 20, GBS, VBIR1 Vaccines Phase 1 & 2 Data Bavencio速 Triplet + 4-1BB + OX-40 Phase 1 Data Xtandi速 nmCRPC PROSPER Submission (US/EU) ACC, FK, GLP1 NASH Phase 1 & 2 Data Vyndaqel速 Cardiomyopathy Phase 3 Data
Discussion

More Related Content

2018 jp morgan final 01.07.18

  • 1. JP Morgan Healthcare Conference A New Era of Pfizer R&D Productivity Mikael Dolsten, M.D., Ph.D. President, Worldwide R&D January 8, 2018
  • 2. Forward-Looking Statements This presentation includes forward-looking statements about, among other things, our in-line products and product candidates, including anticipated regulatory submissions, data read-outs, approvals, performance, timing of exclusivity, potential benefits of Pfizer's products and product candidates, and anticipated future operating and financial performance that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.
  • 3. 12. domagrozumab Duchenne 13. rivipansel Sickle Cell 14. tafamidis Cardiomyopathy 15. tanezumab Pain Step Change in Pfizer R&D Productivity Actual and potential blockbuster approvals (as of January 2018) Up to 15 in 5 Years* Note: Examples reflect when cumulative Peak Year Sales are anticipated to exceed $1B. 1. IO-IO: Mono/Combo 2. IO-Targeted / IO-Chemo 3. Targeted Cancer Agents (Collective) (talazoparib, lorlatinib, dacomitinib, glasdegib) 4. Ibrance速 Intermediate/High Risk eBC 5. Xtandi速 non meta. PROSPER/EMBARK 6. JAK1 Atopic Dermatitis 7. JAK X Alopecia/Vitiligo 8. Xeljanz LCM 9. Clostridium Difficile 10. Staphylococcus Aureus 11. Pneumococcal Nextgen 2005-2010 2011-2016 2017-2022 Inflammation & immunology Oncology Vaccines Rare Disease & Internal Med Pre/Early Wyeth R&D Transformation Return to Growth (Infant ) (Adult) 2 5 *Subject to attrition
  • 4. Potential 2018 Milestones 4 talazoparib EMBRACA Submission (US/EU) Bavencio速 NSCLC 2L Phase 3 Data TFPI mAb Hemophilia Phase 1b/2 Data JAK3 Rheumatoid Arthritis Phase 1 Data Anti IL-33 Atopic Derm Phase 1 Data 1H 2018 2H 2018 LATE STAGE EARLY STAGE Ibrance速 Combo PDAC Phase 1 Data lorlatinib NSCLC 2L Action Date (US) rivipansel Sickle Cell Phase 3 Data tanezumab OA/CLBP Pain Phase 3 Data Xeljanz速 Ulcerative Colitis Action Date (US/EU) Selective JAKs Alopecia, Psoriasis Phase 2 Data PNG 20, GBS, VBIR1 Vaccines Phase 1 & 2 Data Bavencio速 Triplet + 4-1BB + OX-40 Phase 1 Data Xtandi速 nmCRPC PROSPER Submission (US/EU) ACC, FK, GLP1 NASH Phase 1 & 2 Data Vyndaqel速 Cardiomyopathy Phase 3 Data